Zincwarrior
Diamond Member
The Trump Administration announced 100% tariffs on imports of pharmaceuticals to the US. What think USMB?
Trump administration announces new tariffs on drugmakers
The Trump administration said on Thursday that it would impose 100% tariffs on patented pharmaceuticals to force deals for lower drug prices and move manufacturing to America.
Why it matters: It is the latest example of President Trump using tariffs as leverage over corporate America.
Zoom in: The threat of tariffs, which has hung over the pharmaceutical industry for months, helped drive 13 drug companies to make "most-favored nation" pricing deals with the White House late last year.
Trump administration announces new tariffs on drugmakers
The Trump administration said on Thursday that it would impose 100% tariffs on patented pharmaceuticals to force deals for lower drug prices and move manufacturing to America.
Why it matters: It is the latest example of President Trump using tariffs as leverage over corporate America.
Zoom in: The threat of tariffs, which has hung over the pharmaceutical industry for months, helped drive 13 drug companies to make "most-favored nation" pricing deals with the White House late last year.
- It is possible that more companies will strike these voluntary pricing deals with the administration, and the new tariff announcement could be further motivation to do so to be exempted.
- The new tariffs could also spark a wave of industry announcements about domestic manufacturing investments.
- Companies will be exempt from the tariff altogether if they commit to onshore manufacturing and enter into a "most-favored nation" agreement.
- Pharmaceutical companies in Japan, South Korea, Switzerland and the European Union that do not do such deals would be subject to lower tariff rates consistent with previous trade deals.
- The tariffs take effect in 120 days for certain large companies and 180 days for smaller companies.
- The tariffs apply only to branded drugs and their active ingredients. The White House said tariffs on lower-cost generic drugs and biosimilars would be reassessed in a year.
- The senior administration official said they expect all the big, patented pharmaceutical companies to build in the U.S.